NCT03765450View on ClinicalTrials.gov

Pharmacokinetics of IFX and TNF Concentrations in Serum, Stool, and Colonic Mucosa in Acute Severe Ulcerative Colitis

Active, not recruitingOBSERVATIONAL
Enrollment

18

Participants

Timeline

Start Date

December 21, 2018

Primary Completion Date

December 22, 2023

Study Completion Date

March 2, 2026

Conditions
Ulcerative Colitis
Interventions
DRUG

Infliximab

Patients will receive infliximab at the discretion of their physician as part of standard of care.

Trial Locations (3)

10065

Cornell University, New York

92037

UCSD, San Diego

M5G 1X5

Mount Sinai Hospital, Toronto

Sponsors

Lead Sponsor

Alimentiv Inc.
All Listed Sponsors
lead

Alimentiv Inc.

OTHER

NCT03765450 - Pharmacokinetics of IFX and TNF Concentrations in Serum, Stool, and Colonic Mucosa in Acute Severe Ulcerative Colitis | Biotech Hunter | Biotech Hunter